Glimison-M 2 Forte Tablet is a combination oral antidiabetic medication containing Glimepiride 2 mg and Metformin 1000 mg, indicated for the management of type 2 diabetes mellitus. Glimepiride, a sulfonylurea class agent, stimulates pancreatic beta cells to release insulin, thereby reducing blood glucose levels. Metformin, a biguanide, primarily decreases hepatic glucose production and improves peripheral insulin sensitivity, enhancing glucose uptake by muscle tissues. The synergistic action of these agents helps achieve better glycemic control in patients inadequately managed by diet, exercise, or monotherapy. Glimison-M 2 Forte is typically prescribed as part of a comprehensive diabetes management plan including diet, exercise, and regular blood glucose monitoring. It is contraindicated in patients with type 1 diabetes, diabetic ketoacidosis, severe renal or hepatic impairment, and conditions predisposing to hypoxia. Common adverse effects include gastrointestinal disturbances such as nausea, vomiting, diarrhea, and potential hypoglycemia due to Glimepiride. Caution is advised in elderly patients and those with cardiovascular disease. Regular monitoring of blood glucose, renal function, and liver enzymes is recommended during therapy. Dose adjustments should be individualized based on therapeutic response and tolerability. Glimison-M 2 Forte should be used under medical supervision to optimize diabetes control and minimize complications.